The tumor necrosis factor ligand and receptor families

New England Journal of Medicine

Volumn 334, Issue 26, 1996, Pages 1717-1725

  Bazzoni, Flavia ^a   Beutler, Bruce ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; LIGAND; LYMPHOTOXIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ANEMIA; ANTIGENICITY; APOPTOSIS; FEVER; GENE MUTATION; INFLAMMATION; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FAMILY; REVIEW; SIGNAL TRANSDUCTION;

FAS LIGAND PROTEIN; LYMPHOTOXIN-ALPHA; MEMBRANE GLYCOPROTEINS; MOLECULAR STRUCTURE; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029900295     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199606273342607     Document Type: Review

References (80)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A 1975;72:3666-70.
2. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 1984; 312:724-9.
3. Aggarwal BB, Moffat B, Harkins RN. Human lymphotoxin: production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem 1984;259:686-91.
4. Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells. J Exp Med 1985;161:984-95.
5. Beutler B, Greenwald D, Hulmes JD, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985;316:552-4.
6. Kawakami M, Pekala PH, Lane MD, Cerami A. Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. Proc Natl Acad Sci U S A 1982;79:912-6.
7. Pekala PH, Price SR, Horn CA, Horn BE, Moss J, Cerami A. Model for cachexia in chronic disease: secretory products of endotoxin-stimulated macrophages induce a catabolic state in 3T3-L1 adipocytes. Trans Assoc Am Physicians 1984;97:251-9.
8. Torti FM, Dieckmann B, Beutler B, Cerami A, Ringold GM. A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science 1985;229:867-9.
9. Dayer J-M, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8.
10. Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A 1985;82:8667-71.
11. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/ tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-71.
12. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-4.
13. Beutler B, ed. Tumor necrosis factors: the molecules and their emerging role in medicine. New York: Raven Press, 1992.
14. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-kappa B activation. Cell 1995;81:495-504.
15. Song HY, Dunbar JD, Zhang YX, Guo D, Donner DB. Identification of a protein with homology to hsp90 that binds the type 1 tumor necrosis factor receptor. J Biol Chem 1995;270:3574-81.
16. Boldin MP, Mett IL, Wallach D. A protein related to a proteasomal subunit binds to the intracellular domain of the p55 TNF receptor upstream to its 'death domain.' FEBS Lett 1995;367:39-44.
17. Rothe J, Lesslauer W, Lötscher H, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993;364:798-802.
18. Pfeffer K, Matsuyama T, Kündig TM, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73:457-67.
19. Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994;78:681-92.
20. De Togni P, Goellner J, Ruddle NH, et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 1994;264: 703-7.
21. Erickson SL, de Sauvage FJ, Kikly K, et al. Decreased sensitivity to tumournecrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature 1994;372:560-3.
22. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E. The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995;80:389-99.
23. Sato T, Irie S, Kitada S, Reed JC. FAP-I: a protein tyrosine phosphatase that associates with Fas. Science 1995;268:411-5.
24. Boldin MP, Varfolomeev EE, Pancer Z, Mett IL, Camonis JH, Wallach D. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem 1995;270:7795-8.
25. Lee KF, Li E, Huber LJ, et al. Targeted mutation of the gene encoding the low affinity NGF receptor p75 leads to deficits in the peripheral sensory nervous system. Cell 1992;69:737-49.
26. Cheng G, Cleary AM, Ye ZS, Hong DI, Lederman S, Baltimore D. Involvement of CRAF1, a relative of TRAF, in CD40 signaling. Science 1995;267: 1494-8.
27. Hu HM, O'Rourke K, Boguski MS, Dixit VM. A novel RING finger protein interacts with the cytoplasmic domain of CD40. J Biol Chem 1994;269: 30069-72.
28. Sato T, Irie S, Reed JC. A novel member of the TRAF family of putative signal transducing proteins binds to the cytosolic domain of CD40. FEBS Lett 1995;358:113-8.
29. Allen RC, Armitage RJ, Conley ME, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science 1993;259:990-3.
30. Korthäuer U, Graf D, Mages HW, et al. Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM. Nature 1993; 361:539-41.
31. Xu J, Foy TM, Laman JD, et al. Mice deficient for the CD40 ligand. Immunity 1994;1:423-31. [Erratum, Immunity 1994;1:613a.]
32. Kawabe T, Naka T, Yoshida K, et al. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994;1:167-78.
33. Beutler B, Van Huffel C. An evolutionary and functional approach to the TNF receptor/ligand family. Ann N Y Acad Sci 1994;730:118-33.
34. Izui S, Kelley VE, Masuda K, Yoshida H, Roths JB, Murphy ED. Induction of various autoantibodies by mutant gene 1pr in several strains of mice. J Immunol 1984;133:227-33.
35. Roths JB, Murphy ED, Eicher EM. A new mutation, gld, that produces lymphoproliferation and autoimmunity in C3H/HeJ mice. J Exp Med 1984;159: 1-20.
36. Matsuzawa A, Moriyama T, Kaneko T, et al. A new allele of the 1pr locus, 1prcg, that complements the gld gene in induction of lymphadenopathy in the mouse. J Exp Med 1990;171:519-31.
37. Allen RD, Marshall JD, Roths JB, Sidman CL. Differences defined by bone marrow transplantation suggest that 1pr and gld are mutations of genes encoding an interacting pair of molecules. J Exp Med 1990;172:1367-75.
38. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992;356:314-7.
39. Adachi M, Watanabe-Fukunaga R, Nagata S. Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of 1pr mice. Proc Natl Acad Sci USA 1993;90:1756-60.
40. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-78.
41. Rieux-Laucat F, Le Deist F, Hivroz C, et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995;268:1347-9.
42. Fisher GH, Rosenberg FJ, Straus SE, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-46.
43. Browning JL, Ngam-ek A, Lawton P, et al. Lymphotoxin β, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 1993;72:847-56.
44. Crowe PD, VanArsdale TL, Walter BN, et al. A lymphotoxin-β-specific receptor. Science 1994;264:707-10.
45. Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science 1994;264:667-8.
46. Mariathasan S, Matsumoto M, Baranyay F, Nahm MH, Kanagawa O, Chaplin DD. Absence of lymph nodes in lymphotoxin-α(LT α)-deficient mice is due to abnormal organ development, not defective lymphocyte migration. J Inflammation 1995;45:72-8.
47. Engelmann H, Holtmann H, Brakebusch C, et al. Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem 1990;265:14497-504.
48. Tartaglia LA, Goeddel DV, Reynolds C, et al. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol 1993;151:4637-41.
49. Banner DW, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNFβ complex: implications for TNF receptor activation. Cell 1993;73:431-45.
50. Bazzoni F, Alejos E, Beutler B. Chimeric tumor necrosis factor receptors with constitutive signaling activity. Proc Natl Acad Sci U S A 1995;92:5376-80.
51. Boldin MP, Mett IL, Varfolomeev EE, et al. Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem 1995;270: 387-91.
52. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505-12.
53. Stanger BZ, Leder P, Lee T-H, Kim E, Seed B, RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death. Cell 1995;81:513-23.
54. Cleveland JL, Ihle JN. Contenders in FasL/TNF death signaling. Cell 1995; 81:479-82.
55. Tewari M, Quan LT, O'Rourke K, et al. Yama/CPP32β, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 1995;81:801-9.
56. Chittenden T, Harrington EA, O'Connor R, et al. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 1995;374:733-6.
57. Kiefer MC, Brauer MJ, Powers VC, et al. Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak. Nature 1995;374:736-9.
58. Farrow SN, White JHM, Martinou I, et al. Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 1995;374:731-3. [Erratum, Nature 1995;375:431.]
59. Wherry JC, Pennington JE, Wenzel RP. Tumor necrosis factor and the therapeutic potential of anti-tumor necrosis factor antibodies. Crit Care Med 1993;21:Suppl:S436-S440.
60. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor a in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial, JAMA 1995;273:934-41.
61. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
62. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994;344:1125-7.
63. Feldmann M, Brennan FM, Elliott M, Katsikis P, Maini RN. TNF α as a therapeutic target in rheumatoid arthritis. Circ Shock 1994;43:179-84.
64. van Dullemen HM, van Deventer SJH, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995;109:129-35.
65. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991;174:1483-9.
66. Ashkenazi A, Marsters SA, Capon DJ, et al. Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin. Proc Natl Acad Sci U S A 1991;88:10535-9.
67. Kolls J, Peppel K, Silva M, Beutler B. Prolonged and effective blockade of tumor necrosis factor activity through adenovirus-mediated gene transfer. Proc Natl Acad Sci U S A 1994;91:215-9. [Erratum, Proc Natl Acad Sci USA 1994;91:1979.]
68. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
69. Hofmann C, Lorenz K, Braithwaite SS, et al. Altered gene expression for tumor necrosis factor-α and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 1994;134:264-70.
70. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tumor necrosis factor a inhibits signaling from the insulin receptor. Proc Natl Acad Sci U S A 1994;91:4854-8.
71. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor-α. J Clin Invest 1994;94:1543-9.
72. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes 1994;43:1271-8.
73. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993;259:87-91.
74. Spiegelman BM, Hotamisligil GS. Through thick and thin: wasting, obesity, and TNF α. Cell 1993;73:625-7.
75. Spiegelman BM, Choy L, Hotamisligil GS, Graves RA, Tontonoz P. Regulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes. J Biol Chem 1993;268:6823-6.
76. Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature 1988;331:356-8.
77. Jacob CO, Aiso S, Michie SA, McDevitt HO, Acha-Orbea H. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc Natl Acad Sci U S A 1990;87:968-72.
78. Yang X-D, McDevitt HO. Role of TNF-α in the development of autoimmunity and the pathogenesis of insulin-dependent diabetes mellitus in NOD mice. Circ Shock 1994;43:198-201.
79. Yang X-D, Tisch R, Singer SM, et al. Effect of tumor necrosis factor α on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 1994;180:995-1004.
80. Trueb R, Brown G, Van Huffel C, Poltorak A, Valdez-Silva M, Beutler B. Expression of an adenovirally encoded LT-β inhibitor prevents clearance of Listeria monocytogenes in mice. J Inflammation 1996;45:239-47.